{"denoms":[{"counts":[{"groupId":"BG000","value":"134"},{"groupId":"BG001","value":"271"},{"groupId":"BG002","value":"405"}],"units":"Participants"}],"groups":[{"description":"Participants received one of four prespecified, investigator-chosen chemotherapy regimens for 2 induction cycles. Participants who achieved a bone marrow response, CR/CRh\\*/CRi within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of SOC chemotherapy.\n\nParticipants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh\\*/CRi could continue to receive SOC therapy for an additional 12 months.","id":"BG000","title":"Standard of Care Chemotherapy"},{"description":"Participants received blinatumomab by continuous intravenous infusion (CIVI) over 4 weeks followed by a 2 week treatment-free interval for 2 induction cycles. Participants who achieved a bone marrow response, complete remission, or complete remission with partial or incomplete hematologic recovery (CR/CRh\\*/CRi) within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.\n\nParticipants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh\\*/CRi could continue to receive blinatumomab for an additional 12 months (4 cycles), where 1 cycle consisted of 4 weeks of CIVI followed by an 8-week treatment-free period.\n\nThe initial dose of blinatumomab was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 through day 29 and for all subsequent cycles.","id":"BG001","title":"Blinatumomab"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"17.3","value":"41.1"},{"groupId":"BG001","spread":"17.1","value":"40.8"},{"groupId":"BG002","spread":"17.2","value":"40.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"184"}]}],"title":"< 35 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"113"}]}],"title":"35 to 54 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"60"}]}],"title":"55 to 64 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"48"}]}],"title":"≥ 65 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"109"},{"groupId":"BG002","value":"166"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"162"},{"groupId":"BG002","value":"239"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"37"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"122"},{"groupId":"BG001","value":"243"},{"groupId":"BG002","value":"365"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"}]}],"title":"American Indian or Alaska Native"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"28"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"8"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"112"},{"groupId":"BG001","value":"228"},{"groupId":"BG002","value":"340"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}],"title":"Multiple"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"20"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"123"},{"groupId":"BG002","value":"183"}]}],"title":"< 35 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"74"},{"groupId":"BG001","value":"148"},{"groupId":"BG002","value":"222"}]}],"title":"≥ 35 years"}],"paramType":"NUMBER","title":"Age Stratification at Randomization","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"164"},{"groupId":"BG002","value":"244"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"107"},{"groupId":"BG002","value":"161"}]}],"title":"No"}],"paramType":"NUMBER","title":"Prior Salvage Therapy Stratification at Randomization","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"94"},{"groupId":"BG002","value":"140"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"88"},{"groupId":"BG001","value":"177"},{"groupId":"BG002","value":"265"}]}],"title":"No"}],"paramType":"NUMBER","title":"Prior Allogeneic Hematopoietic Stem Cell Transplant (HCST)","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"56"}]}],"title":"FLAG ± anthracycline"},{"categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"30"}]}],"title":"High-dose methotrexate"},{"categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"26"}]}],"title":"Clofarabine"},{"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"22"}]}],"title":"HIDAC"}],"description":"FLAG = fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor (filgrastim); HiDAC = high-dose cytarabine arabinoside","paramType":"NUMBER","title":"Standard of Care Chemotherapy Regimen Received","unitOfMeasure":"participants"}]}